Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6620
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChai MG-
dc.contributor.authorTu Q-
dc.contributor.authorCotta MO-
dc.contributor.authorBauer MJ-
dc.contributor.authorBalch R-
dc.contributor.authorOkafor C-
dc.contributor.authorComans T-
dc.contributor.authorKruger P-
dc.contributor.authorJason Meyer-
dc.contributor.authorShekar K-
dc.contributor.authorBrady K-
dc.contributor.authorFourie C-
dc.contributor.authorSharp N-
dc.contributor.authorVlad L-
dc.contributor.authorWhiley D-
dc.contributor.authorUngerer JPJ-
dc.contributor.authorMcwhinney BC-
dc.contributor.authorFarkas A-
dc.contributor.authorPaterson DL-
dc.contributor.authorJulia Clark-
dc.contributor.authorHajkowicz K-
dc.contributor.authorRaman S-
dc.contributor.authorSeweryn Bialasiewicz-
dc.contributor.authorLipman J-
dc.contributor.authorForde BM-
dc.contributor.authorHarris PNA-
dc.contributor.authorLuregn Schlapbach-
dc.contributor.authorLachlan Coin-
dc.contributor.authorRoberts JA-
dc.contributor.authorAdam D Irwin-
dc.date.accessioned2025-03-29T23:23:51Z-
dc.date.available2025-03-29T23:23:51Z-
dc.date.issued2024-
dc.identifier.urihttps://dora.health.qld.gov.au/qldresearchjspui/handle/1/6620-
dc.description.abstract<h4>Purpose</h4>Early recognition and effective treatment of sepsis improves outcomes in critically ill patients. However, antibiotic exposures are frequently suboptimal in the intensive care unit (ICU) setting. We describe the feasibility of the Bayesian dosing software Individually Designed Optimum Dosing Strategies (ID-ODS™), to reduce time to effective antibiotic exposure in children and adults with sepsis in ICU.<h4>Methods</h4>A multi-centre prospective, non-randomised interventional trial in three adult ICUs and one paediatric ICU. In a pre-intervention Phase 1, we measured the time to target antibiotic exposure in participants. In Phase 2, antibiotic dosing recommendations were made using ID-ODS™, and time to target antibiotic concentrations were compared to patients in Phase 1 (a pre-post-design).<h4>Results</h4>175 antibiotic courses (Phase 1 = 123, Phase 2 = 52) were analysed from 156 participants. Across all patients, there was no difference in the time to achieve target exposures (8.7 h vs 14.3 h in Phase 1 and Phase 2, respectively, p = 0.45). Sixty-one courses in 54 participants failed to achieve target exposures within 24 h of antibiotic commencement (n = 36 in Phase 1, n = 18 in Phase 2). In these participants, ID-ODS™ was associated with a reduction in time to target antibiotic exposure (96 vs 36.4 h in Phase 1 and Phase 2, respectively, p < 0.01). These patients were less likely to exhibit subtherapeutic antibiotic exposures at 96 h (hazard ratio (HR) 0.02, 95% confidence interval (CI) 0.01-0.05, p < 0.01). There was no difference observed in in-hospital mortality.<h4>Conclusions</h4>Dosing software may reduce the time to achieve target antibiotic exposures. It should be evaluated further in trials to establish its impact on clinical outcomes.-
dc.relation.ispartofIntensive care medicine-
dc.titleAchievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis.-
dc.typeJournal Article-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Sites:Queensland Health Publications
Show simple item record

Page view(s)

40
checked on May 8, 2025

Google ScholarTM

Check


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.